SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Intelligent Bio Solutions, Inc. is a medical technology company, which engages in delivering testing solutions. It operates through the Intelligent Fingerprinting Products (IFPG) and Saliva Glucose Biosensor Platform (SGBP) segments. It offers biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was founded on December 5, 2016 and is headquartered in New York, NY.

Intelligent Bio Solutions Inc

Intelligent Bio Solutions (INBS) is trending following news of a strategic manufacturing partnership to scale production of its Intelligent Fingerprinting Drug Screening Reader, ahead of its anticipated U.S. market entry and promising significant operational benefits. The community is actively debating its low float and short squeeze potential, with many discussing whether recent price action is a "stop raid" for further upside or a sign of an impending offering.

Sensei Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company which focuses on the discovery, development, and delivery of next generation immunotherapies for the treatment of cancer and infectious diseases. The company was founded in 1999 and is headquartered in Rockville, MD.

Sensei Biotherapeutics Inc

Sensei Biotherapeutics ($SNSE) is a hot topic as it undergoes a significant corporate restructuring, including discontinuing its lead drug and exploring strategic alternatives like a sale or merger. The immediate catalyst for community conversation is its exceptionally low share float, which is fueling intense speculation about a potential short squeeze. Traders are actively comparing $SNSE to recent parabolic runners, with many anticipating substantial upward momentum despite the company's fundamental changes.

ESH Acquisition Corp. is a blank check company. It was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was founded on November 17, 2021 and is headquartered in New York, NY.

ESH Acquisition Corp - Ordinary Shares - Class A

ESHA is trending due to its volatile price action as a low-float SPAC, prompting intense community discussion around its potential for a short squeeze or significant gains. Traders are closely watching its 'tiny float' and high insider ownership, drawing parallels to other recent 'shell company rippers' amidst sharp price swings and trading halts. This speculative interest sees many buying dips and holding, anticipating further explosive moves.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals is trending following its recent FDA approval of NEREUS, the first new motion sickness treatment in over four decades. Community discussion highlights the drug's significant potential beyond its initial indication, particularly its promising application for GLP-1 induced nausea, which many anticipate could unlock a massive market. This approval, coupled with upcoming pipeline catalysts, fuels widespread speculation about a potential buyout from a larger pharmaceutical entity.

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Axsome Therapeutics Inc

Axsome Therapeutics is trending as the FDA has granted priority review to its supplemental New Drug Application for AXS-05 in Alzheimer's disease agitation, pointing to an accelerated review timeline. This pivotal development, coupled with strong Auvelity sales and anticipated progress toward an NDA for AXS-12 in narcolepsy, is fueling widespread investor optimism. The community is actively discussing Axsome's "best-in-class" pipeline and commercial execution, anticipating significant long-term value appreciation within the CNS therapeutic landscape.

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Redwood City, CA.

Corcept Therapeutics Inc

Corcept Therapeutics experienced a sharp sell-off after the FDA issued a Complete Response Letter for its relacorilant drug in Cushing's syndrome, seeking additional efficacy evidence despite trial success. This dramatic drop has split the community, with many investors calling it an overreaction given the company's profitable Korlym revenue and extensive pipeline, while others remain wary of further downside amid the regulatory uncertainty.

QXO, Inc. is a publicly traded distributor of roofing, waterproofing and complementary building products in the United States. It plans to become tech-enabled in the building products distribution industry and generate outsized value for shareholders. The company was founded on October 3, 2002, and is headquartered in Greenwich, CT.

QXO Inc.

QXO is trending amidst significant debate following recent analyst downgrades that cited its high valuation multiples and softness in the roofing market, driving near-term selling pressure and frustration. Despite this, a substantial part of the community remains bullish, emphasizing CEO Brad Jacobs' successful M&A track record and eagerly awaiting several anticipated acquisitions in the building products distribution sector, viewing current price levels as a strong long-term opportunity.

The Stellar network is an open source, distributed, and community owned network used to facilitate cross-asset transfers of value. Stellar aims to help facilitate cross-asset transfer of value at a fraction of a penny while aiming to be an open financial system that gives people of all income levels access to low-cost financial services. Stellar can handle exchanges between fiat-based currencies and between cryptocurrencies. Stellar.org, the organization that supports Stellar, is centralized like XRP and meant to handle cross platform transactions and micro transactions like XRP. However, unlike Ripple, Stellar.org is non-profit and their platform itself is open source and decentralized.   Stellar was founded by Jed McCaleb in 2014. Jed McCaleb is also the founder of Mt. Gox and co-founder of Ripple, launched the network system Stellar with former lawyer Joyce Kim. Stellar is also a payment technology that aims to connect financial institutions and drastically reduce the cost and time required for cross-border transfers. In fact, both payment networks used the same protocol initially.  Distributed Exchange Through the use of its intermediary currency Lumens (XLM), a user can send any currency that they own to anyone else in a different currency.  For instance, if Joe wanted to send USD to Mary using her EUR, an offer is submitted to the distributed exchange selling USD for EUR. This submitted offer forms is known as an order book. The network will use the order book to find the best exchange rate for the transaction in-order to minimize the fee paid by a user.  This multi-currency transaction is possible because of "Anchors". Anchors are trusted entities that hold people’s deposits and can issue credit. In essence, Anchors serves as the bridge between different currencies and the Stellar network.  Lumens (XLM) Lumens are the native asset (digital currency) that exist on the Stellar network that helps to facilitate multi-currency transactions and prevent spams. For multi-currency transactions, XLM is the digital intermediary that allows for such a transaction to occur at a low cost.  In-order to prevent DoS attacks (aka spams) that would inevitably occur on the Stellar network, a small fee of 0.00001 XLM is associated with every transaction that occurs on the network. This fee is small enough so it does not significantly affect the cost of transaction, but large enough so it dissuades bad actors from spamming the network.   Prior to Protocol 12, Stellar had a built-in inflation mechanism conceived to allow account holders to collectively direct inflation-generated lumens toward projects built on Stellar.  As the network evolved and grew, it became increasingly clear that inflation wasn’t working as intended — account holders either didn’t set their inflation destination or joined inflation pools to claim the inflation themselves, and the operational costs associated with inflation payments continued to rise — and so a protocol change to disable inflation was proposed, implemented, voted on by validators, and ultimately adopted as part of a network upgrade.  The inflation operation is now deprecated. https://developers.stellar.org/docs/glossary/inflation/

Stellar Lumens

Stellar Lumens is trending amid widespread debate over its value proposition, with strong bearish sentiment calling it "garbage" and a "scam" conflicting with bullish expectations for institutional adoption. Despite community skepticism and calls for further declines, renewed focus on its ISO 20022 compliance and ongoing network developments are fueling optimism for a potential rebound.

Alchemy Investments Acquisition Corp. 1 is a blank check company, which engages in merger, share exchange, asset acquisition, share purchase, and reorganization or similar business combination. The company was founded on October 27, 2021 and is headquartered in Newark, DE.

Alchemy Investments Acquisition Corp 1 - Ordinary Shares - Class A

Alchemy Investments Acquisition Corp 1 (ALCY) is trending as the community speculates it could be the next low-float SPAC to see significant price movement, drawing comparisons to recent high-performing SPACs. Discussions highlight the stock's limited circulating shares and increasing volume, with many anticipating a "redemption play" similar to prior market cycles, leading to calls to "load the boat" and expectations for substantial gains.

Oklo, Inc. engages in the development of fission reactors. It provides clean energy through the design and deployment of fast fission power plants. The company was founded by Jacob DeWitte and Caroline Cochran on July 3, 2013 and is headquartered in Santa Clara, CA.

Oklo Inc. - Ordinary Shares - Class A

Oklo Inc.

Oklo is currently trending amidst significant anticipation for a pending Department of Energy announcement regarding awards for surplus plutonium, which could provide the company with crucial, potentially low-cost fuel. The community is actively debating the stock's valuation and the implications of potential zero-cost fuel, with bulls noting signs of institutional accumulation and unusual options activity while bears highlight zero revenue and recent insider selling. This potential award is seen as a game-changer for the small modular reactor company, aligning with the broader demand for carbon-free energy in the AI revolution.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

HAVN Life Sciences, Inc. is a biotechnology company, which provides psychedelic therapies through technology-focused, data-driven, and medical-based solutions. The firm engages in extraction of psychoactive compounds from plants and fungi and the development of natural health care products, and also mental health treatments to support mental health. The company was founded on April 8, 2020 and is headquartered in Port Moody, Canada.

Current Price	$0.0071
Prev Close	$0.013
Open	$0.0071
Dividend Yield	N/A
50-Day Moving Average	$0.0008
Beta	-944.54
Avg. Volume	700.63
PE Ratio	N/A

52-Week High	$0.002
52-Week Low	$0.00
Market Capitalization	$2,600.00
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A
Enterprise Value/EBITDA	N/A

HAVLD
HAVN Life Sciences Inc.

Feed

News

Sentiment

Fundamentals

Info

Latest HAVLD News

HAVLDHAVN Life Sciences Inc.